Obesity increases the risk of heart failure with preserved ejection fraction. Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 ...

The SUMMIT trial found that tirzepatide, a long-acting agonist of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, reduced the risk of the co ...

(RTTNews) - Eli Lilly and Co. (LLY) has released detailed findings from the Phase 3 SUMMIT trial, demonstrating that tirzepatide significantly lowered the risk of worsening heart failure events in ...

As reported in August, the highest dose of tirzepatide tested—15 mg—also helped patients lose an average of 22.9% of their body weight, versus just 2.1% in the trial’s control arm. Patients ...

In an international trial of 713 adults in nine countries including the U.S. called SUMMIT, participants with heart failure with preserved ejection fraction (HFpEF) and obesity taking tirzepatide ...

Eli Lilly and Company (LLY, Financials) said tirzepatide drastically reduced the risk of type 2 diabetes in pre-diabetics and obese or overweight people over 176 weeks; shares rose modestly after ...

CHICAGO, IL—Tirzepatide (Eli Lilly) significantly cut the risk of cardiovascular mortality and worsening heart failure events by nearly 40% over a median follow-up of roughly 2 years in patients with ...

In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown to provide substantial and sustained reductions in body weight in persons with obesity over a 72-week period. Here ...

In a phase-3 randomized controlled trial published in the New England Journal of Medicine, researchers investigated the effects of tirzepatide on weight reduction and diabetes prevention in ...

Findings at week 176 demonstrated that among prediabetic patients treated with tirzepatide (efficacy estimand; pooled doses of 5mg, 10mg, 15mg), 98.8% remained diabetes free. Detailed results were ...

Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients with obesity and HFpEF, compared to placebo. The trial showed significant weight loss and improved insulin ...